Human Infection Challenge with Serotype 3 Pneumococcus
Rationale: Streptococcus pneumoniae serotype 3 (SPN3) is a cause of invasive pneumococcal disease and associated with low carriage rates. Following the introduction of pediatric 13-valent pneumococcal conjugate vaccine (PCV13) programs, SPN3 declines are less than other vaccine serotypes and incidence has increased in some populations coincident with a shift in predominant circulating SPN3 clade, from I to II. A human challenge model provides an effective means for assessing the impact of PCV13 on SPN3 in the upper airway. Objectives: To establish SPN3's ability to colonize the nasopharynx using different inoculum clades and doses, and the safety of an SPN3 challenge model. Methods: In a human challenge study involving three well-characterized and antibiotic-sensitive SPN3 isolates (PFESP306 [clade Ia], PFESP231 [no clade], and PFESP505 [clade II]), inoculum doses (10,000, 20,000, 80,000, and 160,000 cfu/100 μl) were escalated until maximal colonization rates were achieved, with concurrent acceptable safety. Measurement and Main Results: Presence and density of experimental SPN3 nasopharyngeal colonization in nasal wash samples, assessed using microbiological culture and molecular methods, on Days 2, 7, and 14 postinoculation. A total of 96 healthy participants (median age 21, interquartile range 19-25) were inoculated (n = 6-10 per dose group, 10 groups). Colonization rates ranged from 30.0-70.0% varying with dose and isolate. 30.0% (29/96) reported mild symptoms (82.8% [24/29] developed a sore throat); one developed otitis media requiring antibiotics. No serious adverse events occurred. Conclusions: An SPN3 human challenge model is feasible and safe with comparable carriage rates to an established Serotype 6B human challenge model. SPN3 carriage may cause mild upper respiratory symptoms.
| Errataetall: |
CommentIn: Am J Respir Crit Care Med. 2022 Dec 1;206(11):1312-1314. - PMID 35856830 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:206 |
|---|---|
| Enthalten in: |
American journal of respiratory and critical care medicine - 206(2022), 11 vom: 01. Dez., Seite 1379-1392 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 02.12.2022 Date Revised 22.12.2022 published: Print CommentIn: Am J Respir Crit Care Med. 2022 Dec 1;206(11):1312-1314. - PMID 35856830 Citation Status MEDLINE |
|---|
| doi: |
10.1164/rccm.202112-2700OC |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343233703 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343233703 | ||
| 003 | DE-627 | ||
| 005 | 20231226015945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1164/rccm.202112-2700OC |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1144.xml |
| 035 | |a (DE-627)NLM343233703 | ||
| 035 | |a (NLM)35802840 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Robinson, Ryan E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Human Infection Challenge with Serotype 3 Pneumococcus |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.12.2022 | ||
| 500 | |a Date Revised 22.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Am J Respir Crit Care Med. 2022 Dec 1;206(11):1312-1314. - PMID 35856830 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Rationale: Streptococcus pneumoniae serotype 3 (SPN3) is a cause of invasive pneumococcal disease and associated with low carriage rates. Following the introduction of pediatric 13-valent pneumococcal conjugate vaccine (PCV13) programs, SPN3 declines are less than other vaccine serotypes and incidence has increased in some populations coincident with a shift in predominant circulating SPN3 clade, from I to II. A human challenge model provides an effective means for assessing the impact of PCV13 on SPN3 in the upper airway. Objectives: To establish SPN3's ability to colonize the nasopharynx using different inoculum clades and doses, and the safety of an SPN3 challenge model. Methods: In a human challenge study involving three well-characterized and antibiotic-sensitive SPN3 isolates (PFESP306 [clade Ia], PFESP231 [no clade], and PFESP505 [clade II]), inoculum doses (10,000, 20,000, 80,000, and 160,000 cfu/100 μl) were escalated until maximal colonization rates were achieved, with concurrent acceptable safety. Measurement and Main Results: Presence and density of experimental SPN3 nasopharyngeal colonization in nasal wash samples, assessed using microbiological culture and molecular methods, on Days 2, 7, and 14 postinoculation. A total of 96 healthy participants (median age 21, interquartile range 19-25) were inoculated (n = 6-10 per dose group, 10 groups). Colonization rates ranged from 30.0-70.0% varying with dose and isolate. 30.0% (29/96) reported mild symptoms (82.8% [24/29] developed a sore throat); one developed otitis media requiring antibiotics. No serious adverse events occurred. Conclusions: An SPN3 human challenge model is feasible and safe with comparable carriage rates to an established Serotype 6B human challenge model. SPN3 carriage may cause mild upper respiratory symptoms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a SPN3 | |
| 650 | 4 | |a challenge model | |
| 650 | 4 | |a pneumococcus | |
| 650 | 4 | |a serotype 3 | |
| 650 | 7 | |a Pneumococcal Vaccines |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Mitsi, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Nikolaou, Elissavet |e verfasserin |4 aut | |
| 700 | 1 | |a Pojar, Sherin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Reiné, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Nyazika, Tinashe K |e verfasserin |4 aut | |
| 700 | 1 | |a Court, James |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Kelly |e verfasserin |4 aut | |
| 700 | 1 | |a Farrar, Madlen |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez-Dias, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Hamilton, Josh |e verfasserin |4 aut | |
| 700 | 1 | |a Hill, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Hitchins, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Howard, Ashleigh |e verfasserin |4 aut | |
| 700 | 1 | |a Hyder-Wright, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Lesosky, Maia |e verfasserin |4 aut | |
| 700 | 1 | |a Liatsikos, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Matope, Agnes |e verfasserin |4 aut | |
| 700 | 1 | |a McLenaghan, Daniella |e verfasserin |4 aut | |
| 700 | 1 | |a Myerscough, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, Annabel |e verfasserin |4 aut | |
| 700 | 1 | |a Solórzano, Carla |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Duolao |e verfasserin |4 aut | |
| 700 | 1 | |a Burhan, Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Gautam, Manish |e verfasserin |4 aut | |
| 700 | 1 | |a Begier, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Theilacker, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Beavon, Rohini |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Annaliesa S |e verfasserin |4 aut | |
| 700 | 1 | |a Gessner, Bradford D |e verfasserin |4 aut | |
| 700 | 1 | |a Gordon, Stephen B |e verfasserin |4 aut | |
| 700 | 1 | |a Collins, Andrea M |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, Daniela M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of respiratory and critical care medicine |d 1994 |g 206(2022), 11 vom: 01. Dez., Seite 1379-1392 |w (DE-627)NLM074657305 |x 1535-4970 |7 nnns |
| 773 | 1 | 8 | |g volume:206 |g year:2022 |g number:11 |g day:01 |g month:12 |g pages:1379-1392 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1164/rccm.202112-2700OC |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 206 |j 2022 |e 11 |b 01 |c 12 |h 1379-1392 | ||